CSPC Pharmaceutical Group Limited
CSPCY | OTC
$4.07
+$0.13 (+3.30%)
At close: Nov 2, 2026, 3:26 PM ET
$3.94
-$0.13 (-3.19%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q4 2025 Dec 31, 2025 | Q2 2025 Jun 30, 2025 | Q4 2024 Dec 31, 2024 | Q2 2024 Jun 30, 2024 | Q4 2023 Dec 31, 2023 | Q2 2023 Jun 30, 2023 | Q4 2022 Dec 31, 2022 | Q2 2022 Jun 30, 2022 | Q4 2021 Dec 31, 2021 | Q2 2021 Jun 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 18.34B | 12.52B | 13.02B | 12.96B | 16.41B | 15.04B | 16.8B | 15.1B | 16.09B | 13.87B | 13.8B |
Cost of Revenue | 4.37B | 4.31B | 4.48B | 4.16B | 4.67B | 4.33B | 5.06B | 4.34B | 4.4B | 3.39B | 3.29B |
Gross Profit | 13.97B | 8.21B | 8.54B | 8.81B | 11.75B | 10.7B | 11.74B | 10.76B | 11.68B | 10.48B | 10.51B |
Operating Income | 7.24B | 1.38B | 2.52B | 1.69B | 3.72B | 3.44B | 3.64B | 1.45B | 3.57B | 3.09B | 3.11B |
Interest Income | 90.41M | 99.44M | 92.93M | 109.75M | n/a | n/a | n/a | n/a | n/a | 131M | 90M |
Pretax Income | 7.43B | 1.66B | 3.06B | 1.81B | 3.83B | 3.63B | 3.85B | 1.78B | 3.83B | 3.14B | 3.66B |
Net Income | 6.01B | 1.31B | 2.5B | 1.33B | 3.04B | 2.84B | 3.1B | 1.43B | 3.06B | 2.51B | 3.06B |
Selling & General & Admin | 3.73B | 3.76B | 3.45B | 2.1B | 5.46B | 4.79B | 5.69B | 2.75B | 6.17B | 5.59B | 5.79B |
Research & Development | 2.99B | 3.07B | 2.63B | 2.7B | 2.56B | 2.47B | 2.41B | 2.07B | 1.94B | 1.8B | 1.61B |
Other Expenses | n/a | n/a | -60.54M | 2.32B | n/a | n/a | n/a | 2.66B | n/a | n/a | n/a |
Operating Expenses | 6.72B | 6.83B | 6.02B | 7.11B | 8.03B | 7.27B | 8.1B | 7.48B | 8.11B | 7.38B | 7.4B |
Interest Expense | 13.13M | 16.66M | 21.24M | 22.11M | n/a | 9.02M | 6.29M | 18.03M | 6.86M | 3.49M | 5.74M |
Selling & Marketing Expenses | n/a | n/a | 3.05B | 1.85B | n/a | n/a | n/a | 2.49B | n/a | n/a | n/a |
Cost & Expenses | 11.09B | 11.14B | 10.5B | 11.27B | 12.69B | 11.6B | 13.16B | 11.83B | 12.52B | 10.78B | 10.69B |
Income Tax Expense | 1.05B | 381.63M | 533.18M | 499.48M | 755.65M | 678.14M | 651.51M | 311.86M | 713.52M | 597.72M | 552.93M |
Shares Outstanding (Basic) | 11.4B | 11.52B | 11.43B | 11.64B | 11.84B | 11.85B | 11.89B | 11.93B | 11.92B | 11.95B | 11.95B |
Shares Outstanding (Diluted) | 11.42B | 11.52B | 11.43B | 11.64B | 11.84B | 11.85B | 11.89B | 11.93B | 11.92B | 11.95B | 11.96B |
EPS (Basic) | 0.53 | 0.12 | 0.22 | 0.11 | 0.26 | 0.24 | 0.26 | 0.26 | 0.26 | 0.21 | 0.26 |
EPS (Diluted) | 0.53 | 0.12 | 0.22 | 0.11 | 0.26 | 0.24 | 0.26 | 0.26 | 0.26 | 0.21 | 0.26 |
EBITDA | 7.9B | 2.09B | 3.77B | 2.59B | 4.54B | 4.25B | 4.43B | 4.39B | 4.34B | 3.56B | 4.09B |
EBIT | 7.24B | 1.38B | 3.09B | 1.87B | 3.91B | 3.68B | 3.88B | 3.84B | 3.84B | 3.13B | 3.66B |
Depreciation & Amortization | 653.53M | 707.6M | 676.6M | 719.58M | 634.91M | 571.28M | 554.06M | 556.73M | 495.45M | 428.76M | 428.97M |
Add to Watchlist
Select watchlists to add or remove CSPCY